Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Summary

The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded. This means that neither the volunteer or the medical team will know which formulation of the vaccine was administered. The third group of volunteers and the medical team will know that they are receiving the higher dose of the vaccine.

Timeline

Start

2005-12-05

Primary completion

2006-11-30

Completion

2007-12

Drugs

Indications